CADTH Canadian Drug Expert Committee final recommendation: Sapropterin -- resubmission (Kuvan -- BioMarin Pharmaceuticals Canada Inc.) indication: to reduce blood phenylalanine levels in patients with hyperphenylalaninemia due to BH4-responsive phenylketonuria
The CADTH Canadian Drug Expert Committee (CDEC) recommends that sapropterin, in conjunction with a phenylalanine (Phe)-restricted diet, be reimbursed to reduce blood Phe levels in patients with hyperphenylalaninemia (HPA) due to tetrahydrobiopterin (BH4)-responsive phenylketonuria (PKU)
Corporate Authors: | , |
---|---|
Format: | eBook |
Language: | English |
Published: |
Ottawa (ON)
Canadian Agency for Drugs and Technologies in Health
2016, October 26, 2016
|
Series: | CADTH common drug review
|
Subjects: | |
Online Access: | |
Collection: | National Center for Biotechnology Information - Collection details see MPG.ReNa |
Summary: | The CADTH Canadian Drug Expert Committee (CDEC) recommends that sapropterin, in conjunction with a phenylalanine (Phe)-restricted diet, be reimbursed to reduce blood Phe levels in patients with hyperphenylalaninemia (HPA) due to tetrahydrobiopterin (BH4)-responsive phenylketonuria (PKU) |
---|---|
Physical Description: | 1 PDF file (7 pages) |